ニルマトレルビル (Japanese Wikipedia)

臨床試験番号 NCT04535167 研究名 "First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19 " - ClinicalTrials.gov

clinicaltrialsarena.com (Global: low place; Japanese: low place)

“Pfizer begins dosing in Phase II/III trial of antiviral drug for Covid-19.”. Clinical Trials Arena (2021年9月2日). 2021年11月14日閲覧。

doi.org (Global: 2^nd place; Japanese: 6^th place)

Vandyck K, Deval J (August 2021). “Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection”. Current Opinion in Virology 49: 36–40. doi:10.1016/j.coviro.2021.04.006. PMC 8075814. PMID 34029993.
Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang XQ, Clark AE, McMillan RE, Leibel SL, McVicar RN, Xie J, Garretson AF, Smith VI, Murphy J, Hostetler KY (September 2021). “Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs”. Antimicrobial Agents and Chemotherapy 65 (10): e0115521. doi:10.1128/AAC.01155-21. PMC 8448143. PMID 34310217.
Şimşek-Yavuz S, Komsuoğlu Çelikyurt FI (August 2021). “Antiviral treatment of COVID-19: An update”. Turkish Journal of Medical Sciences. doi:10.3906/sag-2106-250. PMID 34391321.
Ahmad B, Batool M, Ain QU, Kim MS, Choi S (August 2021). “Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations”. International Journal of Molecular Sciences 22 (17): 9124. doi:10.3390/ijms22179124. PMC 8430524. PMID 34502033.
Mahase E (October 2021). “Covid-19: UK stockpiles two unapproved antiviral drugs for treatment at home”. BMJ 375: n2602. doi:10.1136/bmj.n2602. PMID 34697079.
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R (June 2003). “Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs”. Science 300 (5626): 1763–1767. doi:10.1126/science.1085658. PMID 12746549.
Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW, Ferre RA, Harr JE, Kosa MB, Worland ST (April 1999). “Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements”. Journal of Medicinal Chemistry 42 (7): 1213–1224. doi:10.1021/jm9805384. PMID 10197965.
Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH (July 2016). “An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy”. Journal of Medicinal Chemistry 59 (14): 6595–6628. doi:10.1021/acs.jmedchem.5b01461. PMC 7075650. PMID 26878082.
Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, Bannasch M, Meadows JM, Chang KO (April 2018). “Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis”. Journal of Feline Medicine and Surgery 20 (4): 378–392. doi:10.1177/1098612X17729626. PMC 5871025. PMID 28901812.
Halford B (7 April 2021). “Pfizer unveils its oral SARS-CoV-2 inhibitor”. Chemical & Engineering News 99 (13): 7. doi:10.47287/cen-09913-scicon3.
Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond H, Hammond J, Haupt RE, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Logue J, Luthra SA, Ma C, Mason SW, McGrath ME, Noell S, Obach RS, O'Brien MN, O'Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers TF, Rossulek MI, Sathish JG, Shirai N, Steppan C, Ticehurst M, Updyke LW, Weston S, Zhu Y, Wang J, Chatterjee AK, Mesecar AD, Frieman MB, Anderson AS, Allerton C (February 2021). “Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19”. bioRxiv: 2020.09.12.293498. doi:10.1101/2020.09.12.293498. PMC 7491518. PMID 32935104.
Owen DR, Allerton CM, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, Dantonio A, Di L, Eng H, Ferre R, Gajiwala KS, Gibson SA, Greasley SE, Hurst BL, Kadar EP, Kalgutkar AS, Lee JC, Lee J, Liu W, Mason SW, Noell S, Novak JJ, Obach RS, Ogilvie K, Patel NC, Pettersson M, Rai DK, Reese MR, Sammons MF, Sathish JG, Singh RS, Steppan CM, Stewart AE, Tuttle JB, Updyke L, Verhoest PR, Wei L, Yang Q, Zhu Y (November 2021). “An oral SARS-CoV-2 M^pro inhibitor clinical candidate for the treatment of COVID-19”. Science: eabl4784. doi:10.1126/science.abl4784. PMID 34726479.

ghc-j.com (Global: low place; Japanese: low place)

gemmed.ghc-j.com

コロナ治療薬ゾコーバ錠の薬価、ラブゲリオとゾフルーザの中間に設定し、1治療当たり5万1851円80銭—中医協総会（2） - GemMed 2023年3月8日

ishikawa.lg.jp (Global: low place; Japanese: 1,123^rd place)

pref.ishikawa.lg.jp

石川県／新型コロナウイルス感染症の経口抗ウイルス薬（パキロビッド）の取扱いについて

mainichi.jp (Global: 278^th place; Japanese: 16^th place)

コロナ飲み薬・パキロビッド、22日から「一般流通」　医師が処方 - 毎日新聞 2023年3月17日

mhlw.go.jp (Global: 1,656^th place; Japanese: 110^th place)

nationalpost.com (Global: 818^th place; Japanese: 3,347^th place)

Nuki P (2021年4月26日). “Pfizer is testing a pill that, if successful, could become first-ever home cure for COVID-19”. National Post. オリジナルの2021年4月27日時点におけるアーカイブ。

nih.gov (Global: 4^th place; Japanese: 24^th place)

pubmed.ncbi.nlm.nih.gov

Vandyck K, Deval J (August 2021). “Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection”. Current Opinion in Virology 49: 36–40. doi:10.1016/j.coviro.2021.04.006. PMC 8075814. PMID 34029993.
Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang XQ, Clark AE, McMillan RE, Leibel SL, McVicar RN, Xie J, Garretson AF, Smith VI, Murphy J, Hostetler KY (September 2021). “Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs”. Antimicrobial Agents and Chemotherapy 65 (10): e0115521. doi:10.1128/AAC.01155-21. PMC 8448143. PMID 34310217.
Şimşek-Yavuz S, Komsuoğlu Çelikyurt FI (August 2021). “Antiviral treatment of COVID-19: An update”. Turkish Journal of Medical Sciences. doi:10.3906/sag-2106-250. PMID 34391321.
Ahmad B, Batool M, Ain QU, Kim MS, Choi S (August 2021). “Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations”. International Journal of Molecular Sciences 22 (17): 9124. doi:10.3390/ijms22179124. PMC 8430524. PMID 34502033.
Mahase E (October 2021). “Covid-19: UK stockpiles two unapproved antiviral drugs for treatment at home”. BMJ 375: n2602. doi:10.1136/bmj.n2602. PMID 34697079.
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R (June 2003). “Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs”. Science 300 (5626): 1763–1767. doi:10.1126/science.1085658. PMID 12746549.
Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW, Ferre RA, Harr JE, Kosa MB, Worland ST (April 1999). “Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements”. Journal of Medicinal Chemistry 42 (7): 1213–1224. doi:10.1021/jm9805384. PMID 10197965.
Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH (July 2016). “An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy”. Journal of Medicinal Chemistry 59 (14): 6595–6628. doi:10.1021/acs.jmedchem.5b01461. PMC 7075650. PMID 26878082.
Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, Bannasch M, Meadows JM, Chang KO (April 2018). “Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis”. Journal of Feline Medicine and Surgery 20 (4): 378–392. doi:10.1177/1098612X17729626. PMC 5871025. PMID 28901812.
Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond H, Hammond J, Haupt RE, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Logue J, Luthra SA, Ma C, Mason SW, McGrath ME, Noell S, Obach RS, O'Brien MN, O'Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers TF, Rossulek MI, Sathish JG, Shirai N, Steppan C, Ticehurst M, Updyke LW, Weston S, Zhu Y, Wang J, Chatterjee AK, Mesecar AD, Frieman MB, Anderson AS, Allerton C (February 2021). “Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19”. bioRxiv: 2020.09.12.293498. doi:10.1101/2020.09.12.293498. PMC 7491518. PMID 32935104.
Owen DR, Allerton CM, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, Dantonio A, Di L, Eng H, Ferre R, Gajiwala KS, Gibson SA, Greasley SE, Hurst BL, Kadar EP, Kalgutkar AS, Lee JC, Lee J, Liu W, Mason SW, Noell S, Novak JJ, Obach RS, Ogilvie K, Patel NC, Pettersson M, Rai DK, Reese MR, Sammons MF, Sathish JG, Singh RS, Steppan CM, Stewart AE, Tuttle JB, Updyke L, Verhoest PR, Wei L, Yang Q, Zhu Y (November 2021). “An oral SARS-CoV-2 M^pro inhibitor clinical candidate for the treatment of COVID-19”. Science: eabl4784. doi:10.1126/science.abl4784. PMID 34726479.

pmc.ncbi.nlm.nih.gov

Vandyck K, Deval J (August 2021). “Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection”. Current Opinion in Virology 49: 36–40. doi:10.1016/j.coviro.2021.04.006. PMC 8075814. PMID 34029993.
Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang XQ, Clark AE, McMillan RE, Leibel SL, McVicar RN, Xie J, Garretson AF, Smith VI, Murphy J, Hostetler KY (September 2021). “Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs”. Antimicrobial Agents and Chemotherapy 65 (10): e0115521. doi:10.1128/AAC.01155-21. PMC 8448143. PMID 34310217.
Ahmad B, Batool M, Ain QU, Kim MS, Choi S (August 2021). “Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations”. International Journal of Molecular Sciences 22 (17): 9124. doi:10.3390/ijms22179124. PMC 8430524. PMID 34502033.
Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH (July 2016). “An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy”. Journal of Medicinal Chemistry 59 (14): 6595–6628. doi:10.1021/acs.jmedchem.5b01461. PMC 7075650. PMID 26878082.
Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, Bannasch M, Meadows JM, Chang KO (April 2018). “Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis”. Journal of Feline Medicine and Surgery 20 (4): 378–392. doi:10.1177/1098612X17729626. PMC 5871025. PMID 28901812.
Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond H, Hammond J, Haupt RE, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Logue J, Luthra SA, Ma C, Mason SW, McGrath ME, Noell S, Obach RS, O'Brien MN, O'Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers TF, Rossulek MI, Sathish JG, Shirai N, Steppan C, Ticehurst M, Updyke LW, Weston S, Zhu Y, Wang J, Chatterjee AK, Mesecar AD, Frieman MB, Anderson AS, Allerton C (February 2021). “Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19”. bioRxiv: 2020.09.12.293498. doi:10.1101/2020.09.12.293498. PMC 7491518. PMID 32935104.

pfizer.com (Global: low place; Japanese: low place)

“Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study”. Pfizer Inc (2021年11月5日). 2021年11月14日閲覧。

racgp.org.au (Global: low place; Japanese: low place)

www1.racgp.org.au

Woodley M (2021年10月19日). “What is Australia's potential new COVID treatment?”. The Royal Australian College of General Practitioners (RACGP). 2021年11月6日閲覧。

wikipedia.org (Global: low place; Japanese: low place)

en.wikipedia.org

臨床試験番号 NCT04535167 研究名 "First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19 " - ClinicalTrials.gov

yomiuri.co.jp (Global: 361^st place; Japanese: 28^th place)

コロナ薬保険適用、ゾコーバ5万2000円・パキロビッドパック9万9000円…当面自己負担なし - 読売新聞 2023年3月8日

ニルマトレルビル (Japanese Wikipedia)

abc.net.au (Global: 139th place; Japanese: 1,039th place)

archive.today (Global: 14th place; Japanese: 320th place)

clinicaltrials.gov (Global: 5,225th place; Japanese: low place)

clinicaltrialsarena.com (Global: low place; Japanese: low place)

doi.org (Global: 2nd place; Japanese: 6th place)

ghc-j.com (Global: low place; Japanese: low place)

gemmed.ghc-j.com

ishikawa.lg.jp (Global: low place; Japanese: 1,123rd place)

pref.ishikawa.lg.jp

mainichi.jp (Global: 278th place; Japanese: 16th place)

mhlw.go.jp (Global: 1,656th place; Japanese: 110th place)

nationalpost.com (Global: 818th place; Japanese: 3,347th place)

nih.gov (Global: 4th place; Japanese: 24th place)

pubmed.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

pfizer.com (Global: low place; Japanese: low place)

racgp.org.au (Global: low place; Japanese: low place)

www1.racgp.org.au

wikipedia.org (Global: low place; Japanese: low place)

en.wikipedia.org

yomiuri.co.jp (Global: 361st place; Japanese: 28th place)

abc.net.au (Global: 139^th place; Japanese: 1,039^th place)

archive.today (Global: 14^th place; Japanese: 320^th place)

clinicaltrials.gov (Global: 5,225^th place; Japanese: low place)

doi.org (Global: 2^nd place; Japanese: 6^th place)

ishikawa.lg.jp (Global: low place; Japanese: 1,123^rd place)

mainichi.jp (Global: 278^th place; Japanese: 16^th place)

mhlw.go.jp (Global: 1,656^th place; Japanese: 110^th place)

nationalpost.com (Global: 818^th place; Japanese: 3,347^th place)

nih.gov (Global: 4^th place; Japanese: 24^th place)

yomiuri.co.jp (Global: 361^st place; Japanese: 28^th place)